HealthQuill Drugs
Israel’s Teva Pharmaceutical Industries Ltd’s, Weltruza, a once-monthly injection for treatment of schizophrenia in adults, has been approved by the US Food and Drug Administration.
Drugs Health Pharma

Israel’s Teva gets FDA nod for treating schizophrenia in adult patients

HQ Team October 10, 2026: Israel’s Teva Pharmaceutical Industries Ltd’s, Weltruza, a once-monthly injection for treatment of schizophrenia in adults, has been approved.

Read More
The US Food and Drug Administration has approved Asahi Kasei Therapeutics, Inc’s oral drug to treat mucocutaneous lesions caused by herpes simplex virus (HSV) for adults with weakened immune systems.
Drugs Health Pharma

FDA clears Asahi Kasei’s oral drug to treat herpes virus in immunodeficient

The US Food and Drug Administration has approved Asahi Kasei Therapeutics, Inc’s oral drug to treat mucocutaneous lesions caused by herpes simplex virus.

Read More
GSK Plc will invest $800 million in Montgomery, Pennsylvania to build a biopharmaceutical innovation and manufacturing hub, according to the state governor Josh Shapiro.
Drugs Medical Pharma

GSK Plc to invest $800 million in Pennsylvania for biopharma hub

GSK Plc will invest $800 million in Montgomery, Pennsylvania to build a biopharmaceutical innovation and manufacturing hub, according to the state governor Josh.

Read More
The East African nation of Kenya confirmed its first case of Ebola after one of its citizens who flew into the capital, Nairobi, died of the disease.
Drugs Health Medical

Kenya confirms first confirmed case of Ebola virus, citizen came from Congo

The East African nation of Kenya confirmed its first case of Ebola after one of its citizens who flew into the capital, Nairobi,.

Read More
New York Governor Kathy Hochul declared a state of emergency in the most populous city in the United States over a measles outbreak.
Drugs Health Medical

New York State issues emergency order to fight measles surge

New York Governor Kathy Hochul declared a state of emergency in the most populous city in the United States over a measles outbreak.

Read More
Non-communicable diseases (NCDs) accounted for eight of the world’s ten leading causes of death in 2023, up from 58% in 2000, according to a report by the World Health Organization.
Drugs Health Medical

Non-communicable diseases account for 74% of global deaths: WHO

HQ Team October 5, 2026:  Non-communicable diseases (NCDs) accounted for eight of the world’s ten leading causes of death in 2023, up from.

Read More
China’s Abogen Biosciences has signed a $7.8 billion licensing and option pact with Novartis AG to make messenger RNA-encoded therapies, which have the potential to treat autoimmune diseases in a more advanced form than the existing ones.
Drugs Health Pharma

Novartis inks $7.8b deal with China’s Abogen for mRNA trial therapy

HQ Team October 4, 2026: China’s Abogen Biosciences has signed a $7.8 billion licensing and option pact with Novartis AG to make messenger.

Read More
Novo Nordisk A/S or Novo, has partnered with UNICEF to expand their global partnership for four years to fight childhood overweight and obesity, and the Danish company has committed $18 million until 2030.
Drugs Health Medical

Novo-UNICEF extends pact to fight child obesity, Novo to pump in $18m

HQ Team September 23, 2026: Novo Nordisk A/S or Novo, has partnered with UNICEF to expand their global partnership for four years to.

Read More
The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in patients two years of age and older who have responded inadequately to, or who are intolerant to, one or more disease-modifying anti-rheumatic drugs.
Drugs Health Pharma

EC approves AbbVie Inc.s drug for a type of juvenile idiopathic arthritis

HQ Team September 22, 2026: The European Commission has approved AbbVie Inc.’s drug for the treatment of active polyarticular juvenile idiopathic arthritis in.

Read More
American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment of manic episodes in adults with bipolar I disorder, according to the company.
Drugs Pharma Research

J&J’s test drug for manic episodes in bipolar disorder meets main goal

HQ Team September 22, 2026: American pharmaceutical company Johnson & Johnson’s investigational drug met its main goal during end-stage trials for the treatment.

Read More